Methods of use and pharmaceutical combinations of HDAC inhibitors with BET inhibitors
US11298354B2 · kind B2 · utility
1Cited by
0References
11Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 9, 2017 |
| Grant date | Apr 12, 2022 |
| Priority date | — |
| Expiry date | Feb 19, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a BET inhibitor for the treatment of cancer in a subject in need thereof. Also provided herein are methods for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC6 selective inhibitor and a BET inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.